Pfizer Seeks New Homes For Assets Orphaned By R&D Reorg
This article was originally published in The Pink Sheet Daily
Executive Summary
New head of out-licensing takes on prospects cast off in Pfizer’s recent exit from non-“high priority” therapeutic areas.